# US 10,370,435 B2 · Binding molecules directed against influenza hemagglutinin and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,435 B2
- Document ID: US10370435B2
- Status: Granted
- Kind: B2
- Application number: 15/548,843
- Filed: 2016-02-05
- Published: 2018-01-18
- Granted: 2019-08-06
- Earliest claimed: 2015-02-05
- Assignees: Janssen Vaccines & Prevention B.V.
- Applicants: Janssen Vaccines & Prevention B.V.
- Inventors: Boerries Brandenburg; Ronald Vogels; Joost A. Kolkman; Robert Heinz Edward Friesen
- Web page: https://patentgrep.com/patent/US10370435B2

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- C07K 16/08: against material from viruses
- G01N 33/56983: {Viruses}
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/526: CH3 domain
- C07K 2317/62: comprising only variable region components
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

## Claims

### Claim 1

A multi-domain antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 303 and SEQ ID NO:305.

### Claim 2 (depends on 1)

The multi-domain antibody according to claim 1, comprising the amino acid sequence of SEQ ID NO:303 and the amino acid sequence of SEQ ID NO:305.

### Claim 3

A multi-domain antibody comprising a first polypeptide comprising two single domain antibodies fused together via a linker, wherein the two single domain antibodies comprise the amino acid sequences of SEQ ID NOs: 155, and 176, respectively.

### Claim 4 (depends on 3)

The multi-domain antibody according to claim 3, further comprising a second polypeptide comprising two single domain antibodies fused together via a linker, wherein the two single domain antibodies comprise the amino acid sequences of SEQ ID NOs: 221 and 203, respectively.

### Claim 5 (depends on 3)

The multi-domain antibody according to claim 3, further comprising a human Fc tail.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the multi-domain antibody according to claim 1.

### Claim 7 (depends on 3)

A pharmaceutical composition comprising the multi-domain antibody according to claim 3.

### Claim 8 (depends on 1)

A nucleic acid molecule encoding the multi-domain antibody according to claim 1.

### Claim 9 (depends on 3)

A nucleic acid molecule encoding the multi-domain antibody according to claim 3.